ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1228

Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials

Clifton Bingham III1, Bochao Jia2, Jianmin Wu2, Amanda Quebe2, Carol Kannowski2, Susan Otawa2, Yun-Fei Chen2, Kirstin Griffing2, Dongyi He3 and Dalton Sholter4, 1Johns Hopkins University, Baltimore, MD, 2Eli Lilly and Company, Indianapolis, IN, 3Shanghai Guanghua Hospital, Shanghai, Shanghai, China (People's Republic), 4University of Alberta, Edmonton, AB, Canada

Meeting: ACR Convergence 2020

Keywords: Disease Activity, Disease-Modifying Antirheumatic Drugs (Dmards), Patient reported outcomes

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 8, 2020

Session Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Baricitinib (BARI) improved patient-reported outcomes (PROs) in patients with insufficient response or intolerance to ≥1 tumor necrosis factor inhibitors (TNFi) or other biological disease-modifying antirheumatic drugs (bDMARDs) as well as in patients with inadequate response (IR) to conventional synthetic DMARDs (csDMARDs).1,2 The purpose of this analysis was to determine the association between improvement in PROs (pain, physical function, fatigue, and morning joint stiffness) and disease activity (measured using Clinical Disease Activity Index [CDAI] at 12 weeks. We evaluated whether BARI 2-mg provided greater PRO improvement compared to placebo (PBO), across all levels of disease activity.

Methods: Data for these post-hoc analyses were taken from two phase 3 studies, RA-BEACON (NCT01721044; bDMARD-IR patients) and RA-BUILD (NCT01721057; csDMARD-IR patients). Pain was assessed on a 0-100 mm visual analog scale; physical function was assessed using the Health Assessment Questionnaire-Disability Index (HAQ-DI); and fatigue was measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale. Duration of morning joint stiffness (MJS, minutes) was also reported by the patient. Disease activity was assessed with the Clinical Disease Activity Index (CDAI) and categorized as: remission (≤2.8), low disease activity (LDA; >2.8 to ≤10), moderate disease activity (MDA; >10 to ≤22), high disease activity (HDA; >22). To evaluate the extent of benefit in PROs with BARI across disease activity levels at Week 12 relative to PBO, we used linear regression to model the relationship between change in PROs at Week 12 (response), and CDAI values at Week 12 (primary explanatory variable). Two additional variables included were treatment group and the interaction term between treatment and CDAI. We used last observation carried forward to impute missing values.

Results: At 12 weeks in bDMARD-IR patients, BARI 2-mg demonstrated greater improvements in pain, physical function, fatigue and MJS duration across all disease activity levels vs. placebo group (Figure 1). In csDMARD-IR patients, BARI 2-mg provided greater improvement in PROs (pain, HAQ-DI, MJS and fatigue) for patients who achieved disease control (remission or LDA) compared to placebo group. Greater reduction in pain and MJS duration were also observed in BARI 2-mg patients with MDA or HDA relative to placebo (Figure 2).

Conclusion: BARI 2-mg provided greater improvements in pain, physical function, fatigue and MJS duration across all levels of disease activity in bDMARD-IR patients and csDMARD-IR patients who achieved remission or LDA. Greater reduction in pain and MJS duration were also observed in csDMARD-IR patients with MDA or HDA at Week 12.

References:

  1. Smolen et al. Ann Rheum Dis. 2017;76(4):694-700.
  2. Emery et al. RMD Open. 2017;3(1):e000410.

Figure 1: Estimated changes in PROs by CDAI disease activity at Week 12 in RA-BEACON (bDMARD-IR) trial. A) Pain VAS, B) HAQ-DI, C) FACIT-F, D) Duration of MJS.

Figure 2: Estimated changes in PROs by CDAI disease activity at Week 12 in RA-BUILD (csDMARD-IR) trial. A) Pain VAS, B) HAQ-DI, C) FACIT-F, D) Duration of MJS.


Disclosure: C. Bingham III, Bristol-Myers Squibb, 2, 5, 8, Genetech, 5, 8, Sanofi, 5, 8, AbbVie, 5, Eli Lilly, 5, Pfizer, 5, Gilead Sciences, Inc., 5, Regeneron, 5; B. Jia, Eli Lilly and Company, 1, 3; J. Wu, Eli Lilly and Company, 1, 3; A. Quebe, Eli Lilly & Co., 1, 2; C. Kannowski, Eli Lilly and Company, 1, 3; S. Otawa, Eli Lilly and Company, 1, 3; Y. Chen, Eli Lilly and Company, 1, 3; K. Griffing, Eli Lilly and Company, 1, 3; D. He, None; D. Sholter, None.

To cite this abstract in AMA style:

Bingham III C, Jia B, Wu J, Quebe A, Kannowski C, Otawa S, Chen Y, Griffing K, He D, Sholter D. Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/baricitinib-2-mg-provides-greater-improvements-in-patient-reported-outcomes-across-all-disease-activity-levels-compared-to-placebo-post-hoc-analyses-of-ra-beacon-and-ra-build-trials/. Accessed February 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baricitinib-2-mg-provides-greater-improvements-in-patient-reported-outcomes-across-all-disease-activity-levels-compared-to-placebo-post-hoc-analyses-of-ra-beacon-and-ra-build-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.